Features Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Features Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.

Features At Work With: Adam Scott Roberts

At Work With: Adam Scott Roberts

Adam Scott Roberts, Senior Vice President, Group Media Director, Communications Media Inc.

Features Upward Move: Maggie Helmig

Upward Move: Maggie Helmig

Maggie Helmig, EVP, global brand lead, Ogilvy CommonHealth

Features

People Moves: April 2014

Promotions and hires for manufacturers and agencies

Features Headliner: Pharma's type "A" exec—and mentor

Headliner: Pharma's type "A" exec—and mentor

Brian Goff, Global franchise head for hemophilia, Baxter

Features Non-Personal Promotion: A New Era in E-Sampling

Non-Personal Promotion: A New Era in E-Sampling

Sales force success in the new world of prescribing takes technology. Harris Kaplan and Ann Mayer say substituting e-sampling for rep time could be a game changer for specialty brands. Why this tactic's time is now

Features Rare Diseases: Orphans in Danger

Rare Diseases: Orphans in Danger

For rare diseases and orphan products, the future looks promising, but as Peter Saltonstall finds, significant research, educational and policy challenges remain. A view from one of the patient community's staunchest advocates

Features Therapeutic Focus 2014: Respiratory

Therapeutic Focus 2014: Respiratory

With generics firms taking aim at high-flying blockbusters, Big Pharma stalwarts in the asthma and COPD market are pinning their hopes for the future on a flurry of innovative biotech-developed assets. Noah Pines charts the rarefied air of the respiratory space

Features DTC Report: 10 Riskiest DTC Ads Ever

DTC Report: 10 Riskiest DTC Ads Ever

Here's a countdown of 10 risk-taking ads—five that our industry experts thought truly succeeded, followed by five that might have done better. It's our shout-out to brands that took a risk.

Features DTC Report: DTC Gets Smart

DTC Report: DTC Gets Smart

Given the adoption of in-app video and gaming, forward-looking pharma marketers are experimenting with so-called smart DTC on small screens—and the skeptics might not be able to stand in their way much longer

Features How to establish brand preference among HCPs

How to establish brand preference among HCPs

Prescribing decisions have become tied to potential therapeutic benefits and the total "Patient Experience"

Features

Broadcast DTC risk info could shrink

FDA's Office of Prescription Drug Promotion (OPDP) plans to research the effects that could follow changing the risk information the agency requires to be included in such direct-to-consumer ads.

Features As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications

Features Agency Business briefs:April 2014

Agency Business briefs:April 2014

News on N.S. Bienstock, Ogilvy CommonHealth, AbelsonTaylor and TGaS

Features LEO Pharma and Edelman extend their partnership

LEO Pharma and Edelman extend their partnership

LEO Pharma has inked an extension for its public relations contract with Edelman's Frankfurt, Germany office, according to news outlet PMLiVE.

Features

Checklist to gauge real-world studies

Researchers have developed and tested a checklist that aims to evaluate comparative effectiveness research and distinguish real-world studies that are good enough for decision-making about treatments.

Features Vantage Point: Marketing Support for Clinical Trials

Vantage Point: Marketing Support for Clinical Trials

Pharmaceutical companies must provide robust marketing support for their clinical trials

Features DDR on DTC: Nexium

DDR on DTC: Nexium

AZ has taught us a lot about acid reflux disease over the years, but the latest Nexium campaign looks like the creative team simply gave up

Features Digital Media briefs: April 2014

Digital Media briefs: April 2014

News on the Journal of the American Medical Association, the National Multiple Sclerosis Society and FDA

Features

Are rep networks a solid resource?

Research shows HCPs bounce from site to site, so rep networks seem to offer both one-stop info shopping and industry contact. But do they provide quality interaction, or are they just a way to e-mail marketing materials?

Features Professional Media briefs: April 2014

Professional Media briefs: April 2014

News on MedCAREERS Group Inc., F1000 and the American Academy of Orthopaedic Surgeons

Features

A research gap for rare diseases

There is an "overwhelming need" among HCPs for greater awareness, training and education on the diagnosis and available treatment options for rare diseases, researchers suggest.

Features

Speaker pay sharply cut: ProPublica

The approach of new transparency rules, coupled with patent losses and industry's shift to specialty meds, has contributed to a big drop in the amount drugmakers are spending on promotional speaking, says ProPublica.

Features Professional Marketing briefs: April 2014

Professional Marketing briefs: April 2014

News on Physicians Interactive, National Association of Boards of Pharmacy and Roche

Features Endo reaches settlement with DOJ over Lidoderm claims

Endo reaches settlement with DOJ over Lidoderm claims

Endo Pharmaceuticals became the latest drugmaker to ink an off-label marketing settlement, paying $192.7 million to resolve charges it promoted pain patch Lidoderm for unapproved uses

Features Playing the name game with biosimilars

Playing the name game with biosimilars

Allowing copies of branded biologic medicines to share the original drug's non-proprietary name will have little or no consequence for patient safety, most stakeholders and experts said during a February workshop convened by FTC

Features Storied in great content

Storied in great content

Content marketing is no mystery. It's just the art of sharing good stories

Features Game Changers 2014

Game Changers 2014

Contact information for companies

Features Game-changing companies

Game-changing companies

MM&M's showcase of healthcare marketing, communications, tech, media and ­research companies that are helping to shape the future of the industry.

Features Read the 2014 Game Changers digital edition

Read the 2014 Game Changers digital edition

Click the above link to access the complete Digital Edition of the 2014 Game Changers issue, with all text, charts and pictures.

Features Read the complete 2014 MM&M Digital Guide digital edition

Read the complete 2014 MM&M Digital Guide digital edition

Click the above link to access the complete Digital Edition of the 2014 MM&M Digital Guide, with all text, charts and pictures.

Features

Companies at a glance

Features Digital Think Tank: A Work in Progress

Digital Think Tank: A Work in Progress

Five digital healthcare experts offer elevator insights on the state of digital pharma—the ups, the downs and how to get to the next level

Features Technology: What Happened in Vegas...

Technology: What Happened in Vegas...

Digital health continued to find a home at the annual consumer electronics shindig in the desert, with fitness, wellness and medical exhibitors up 30%. AstraZeneca's Joe Shields walked the halls to check out what's hot in health tech

Features Regulatory Compliance: Social Commentary

Regulatory Compliance: Social Commentary

At last the FDA has offered some semblance of guidance for digital promotional activities in the medical space. Was it worth the wait? And will it change anything? Peter Pitts picks it apart

Features Overview: Life is but a Screen

Overview: Life is but a Screen

If you still crave the comfort of referring to mobile, social media and other digital components as "channels," then at least consider renaming them "human channels." James Chase reports

Features Read the complete March 2014 Digital Edition

Read the complete March 2014 Digital Edition

Click the above link to access the complete Digital Edition of the March 2014 issue, with all text, charts and pictures.

Features DIgital Media briefs: March 2014

DIgital Media briefs: March 2014

News on IBM, Google, Glooko and Welltok

Features Headliner: Leading the fight against infection

Headliner: Leading the fight against infection

Carrie Bourdow, Vice president, marketing, Cubist Pharmaceuticals

Features How to raise your brand's social media profile

How to raise your brand's social media profile

Social media marketing has the best reach and results when it is part of a larger digital marketing strategy

Features Payers must reach millennials for ACA to work

Payers must reach millennials for ACA to work

Now is the time for insurers to invest in differentiating their brand among younger and healthier people

Features Breakthrough requests swamp FDA

Breakthrough requests swamp FDA

FDA's drug center says it has been so overwhelmed with industry's response to its new Breakthrough Therapy program that it is becoming difficult to promise an "all hands" commitment.

Features Waxman, a tough critic of industry, is retiring

Waxman, a tough critic of industry, is retiring

California Democrat Henry Waxman, one of the strongest FDA overseers and drug industry critics on Capitol Hill, will step down when the House of Representatives adjourns for the mid-term elections

Features Agency Business briefs: March 2014

Agency Business briefs: March 2014

News on Rosetta, StoneArch and Intouch Solutions

Features LIlly comes on board at think tank

LIlly comes on board at think tank

National Pharmaceutical Council (NPC) said Eli Lilly joined earlier this year

Features Vantage Point: Boosting Quality, Containing Costs

Vantage Point: Boosting Quality, Containing Costs

A new industry has emerged to provide analytics and predictive tools that support optimized care

Features

OTC side effects prompt concerns

Consumers are paying attention to OTC side effects, a study by research firm Mintel shows

Features DDR on DTC: Latuda

DDR on DTC: Latuda

Latuda, a new bipolar anti-depression brand from Sunovion, has joined the DTC fray with an integrated campaign targeted at women betweeen 25 and 49.

Features

Professional Media briefs: March 2014

News on PLOS, PMLiVE and Elsevier

Features Wolters Kluwer broadens the focus of Nursing Advisor

Wolters Kluwer broadens the focus of Nursing Advisor

Wolters Kluwer Health has renamed Lippincott's Nursing Advisor the Lippincott Advisor

Features MPR marks a few digital milestones

MPR marks a few digital milestones

Within four days, drug resource MPR hit two milestones of note: reaching one million monthly views as of February 3 and moving from a soft launch to an all-out shout of its MPR app on February 7.

Features Med Ed Report briefs: March 2014

Med Ed Report briefs: March 2014

News on the CBI Pharmaceutical Compliance Congress, Eli Lilly and New York TImes

Features Alexion ramps up med-ed for HPP drug

Alexion ramps up med-ed for HPP drug

Alexion is focusing on medical education ahead of an anticipated approval of asfotase alfa for patients with hypophosphatasia, or HPP

Features Professional Marketing briefs: March 2014

Professional Marketing briefs: March 2014

News on Johnson & Johnson, Novartis and Merck

Features Ashfield's name and services expand

Ashfield's name and services expand

Ashfield unites its businesses under the Ashfield Commercial & Medical Services banner

Features Insight trumps innovation

Insight trumps innovation

At any given time, 25-40% of your staff don't know how to do their jobs

Features Putting moves on Big Data

Putting moves on Big Data

It's time to make healthcare data Big, and for patients' sake, sexy

Features At Work With: Jack Hyndman

At Work With: Jack Hyndman

Jack Hyndman, Creative, Fingerpaint

Features Upward Move: Ceci Zak

Upward Move: Ceci Zak

Ceci Zak, Chief operating officer, Diversified Agency Services, Omnicom

Features

People Moves: March 2014

Promotions and hires for manufacturers, agencies and regulatory

Features Private View: Telling good brand stories

Private View: Telling good brand stories

Good stories feel as if they're meant for us, and they stay with us.

Features MM&M Awards: How to Win

MM&M Awards: How to Win

You have less than eight weeks left to enter the MM&M Awards. No problem. Give yourself the best chance of success by following our checklist of Dos and Don'ts. Good luck!

Features MAHF 2014: Honoring Our Heroes

MAHF 2014: Honoring Our Heroes

Hundreds of industry execs assembled in New York to pay tribute to the careers of the 2014 MAHF honorees

Features Therapeutic Focus 2014: Metabolic

Therapeutic Focus 2014: Metabolic

The launch front in this category is relatively calm—for now. A movement is brewing to unseat the top diabetes drug, a long-acting insulin, as faster-acting products emerge. Joe Dysart on the intrigue in the metabolic pipeline

Features Specialty Pharma: Coverage at the Crossroads

Specialty Pharma: Coverage at the Crossroads

As orphan and specialty drugs account for a larger part of total spend, insurers say a barrage of tactics are needed to manage costs. Sarah Morgan on why this is a defining moment

Features Journal Ad Review: Paper Chase

Journal Ad Review: Paper Chase

The downward spiral for journals continues. Is anyone surprised? Larry Dobrow on how the fundamental shift to digital continued to affect professional media last year, including the full-year numbers by advertisers and brands

Features Data & Analytics: New Frontiers for Big Data

Data & Analytics: New Frontiers for Big Data

Five areas in which innovative uses of data and analytics promise to improve outcomes along the healthcare continuum. Marc Iskowitz reports

Features Read the complete February 2014 Digital Edition

Read the complete February 2014 Digital Edition

Click the above link to access the complete Digital Edition of the January 2014 issue, with all text, charts and pictures.

Features Agencies, get over your fear

Agencies, get over your fear

Success cures fear, and success is born out of focus and hard work

Features At Work With: Martin O'Brien

At Work With: Martin O'Brien

Martin O'Brien, Partner, Rosetta

Features Upward Move: Erik Hawkinson

Upward Move: Erik Hawkinson

Erik Hawkinson, Managing director, WCG

Features

People Moves: February 2014

Promotions and hires for manufacturers and agencies

Features Private View: Hitting the boomer target

Private View: Hitting the boomer target

These ads take aim at the aging male population. How well do they do at hitting their target?

Features Headliner: A commander in GSK's air corps

Headliner: A commander in GSK's air corps

Jorge Bartolome, SVP, US respiratory, GlaxoSmithKline

Features Non-Personal Promotion: Devil in the Detail

Non-Personal Promotion: Devil in the Detail

Tactical ROIs aside, pharma must go beyond the detail to create longer-term value, say Croom Lawrence and Kent Groves, who offer a few tips for new brands

Features MM&M Awards 2014 launches

MM&M Awards 2014 launches

The MM&M Awards 2014 program is officially open for business. This is your chance to put your best work—and people —forward and get the recognition you deserve.

Features Medical Advertising Hall of Fame 2014: Honor Roll

Medical Advertising Hall of Fame 2014: Honor Roll

The four newest luminaries honored by the Medical Advertising Hall of Fame built sterling reputations as they advanced their fields. Joshua Slatko looks back on their success and on how each came to be synonymous with their particular niche of healthcare marketing

Features Therapeutic Focus 2014: Rare Diseases

Therapeutic Focus 2014: Rare Diseases

"New and improved" has entered this space. Alongside the existing compounds that are transforming the lives of patients with orphan ailments, a wave of incrementally better products is coming out. Noah Pines reviews the significant rare-disease market trends

Features Managed Markets: Operation Patient-Centricity

Managed Markets: Operation Patient-Centricity

As the Affordable Care Act rolls out, the behaviorists at MicroMass surveyed stakeholders about the impact on industry. Jessica Brueggeman sorts out the diverse views and asks: Can healthcare reform lead pharma to operationalize its patient focus?

Features Mobile Marketing Report: The Wellness Game

Mobile Marketing Report: The Wellness Game

Pharma has reduced the burden of disease. It can develop a condition-specific app. But getting people to take their medications as prescribed? That's another matter. Larry Dobrow on why biopharma is backing mobile games for their potential to boost adherence and drive behavior change

Features

FDA stand on compounding criticized

Public Citizen has written FDA asking it to stop making "misleading" statements about pharmacy compounding

Features Supreme Court declines drug free-speech case

Supreme Court declines drug free-speech case

The US Supreme Court has declined, without comment, to hear a closely watched appeal by former InterMune CEO Scott Harkonen on whether someone can be prosecuted for speaking truthfully about a drug.

Features Agency Business briefs: February 2014

Agency Business briefs: February 2014

News on Havas, Fingerpaint Marketing, 3D Communications and Ogilvy

Features

Platform links up PAs and patients

Liberate Ideas and the American Academy of Physicians Assistants are rolling out the Liberate Health platform to give physician assistants more tools to communicate with patients

Features DDR on DTC: Belviq

DDR on DTC: Belviq

Belviq has launched a DTC campaign that positions weight-loss as being about health

Features Jackson enlisted in Stand Up to Cancer campaign

Jackson enlisted in Stand Up to Cancer campaign

The six-year-old research group Stand Up To Cancer is featuring Samuel L. Jackson in its "In Play" campaign.

Features Digital Media briefs: February 2014

Digital Media briefs: February 2014

News on Merck, TGaS Advisors, Johnson & Johnson and AdhereTech

Features How do we make the mobile move?

How do we make the mobile move?

With physicians and patients engaging in more cross-platform behavior, marketers must be multi-screen to reach them. Yet only one-third of pharma sites are mobile-optimized. Can we catch up with our customers?

Features Professional Media briefs: February 2014

Professional Media briefs: February 2014

News on Doximity, Hepatic Oncology and media group F1000

Features Med Ed Report briefs: February 2014

Med Ed Report briefs: February 2014

News on the Federation of State Medical Boards, Haymarket Medical Education, ACCME and the Audio-Digest Foundation

Features CMS: journal reprints fall outside of Sunshine exclusion

CMS: journal reprints fall outside of Sunshine exclusion

It looks like, for now, journal reprints and medical textbooks are reportable items under the Sunshine Act.

Features ACCME revisits commercial logo ban

ACCME revisits commercial logo ban

The ACCME announced a public call for comment about its proposal to simplify the accreditation requirements and process, including revisiting a ban on commercial support logos.

Features Professional Marketing briefs: February 2014

Professional Marketing briefs: February 2014

News on Aegerion, Vivus, Merck and Gilead

Features NuvaRing: another ethical crisis at Merck

NuvaRing: another ethical crisis at Merck

The ethical spotlight is once again pointed at Merck & Co., Inc. In December, Vanity Fair put a human face on the controversy swirling around the company's Nuva­Ring contraception product.

Features Shiny objects with meaning

Shiny objects with meaning

Gaming does not trivialize the patient's experience of a chronic disease

Features Read the complete 2013 MM&M Awards Book of the Night digital edition

Read the complete 2013 MM&M Awards Book of the Night digital edition

Click the above link to access the complete Digital Edition of the 2013 MM&M Awards Book of the Night, with all text, charts and pictures.

Features Read the complete January 2014 Digital Edition

Read the complete January 2014 Digital Edition

Click the above link to access the complete Digital Edition of the January 2014 issue, with all text, charts and pictures.

Features

RTI to study DTC ad response for FDA

Under a $4-million contract from FDA, RTI International researchers will look at consumers' responses to risk, benefit and cost information in direct-to-consumer prescription drug ads

Email Newsletters